Intelligent Bio Solutions Inc. Announces Reverse Stock Split

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) will effect a 1‑for‑10 reverse stock split at 11:59 PM ET on December 15, 2025, with split‑adjusted trading resuming on Nasdaq at the open on December 16, 2025 under the symbol INBS and new CUSIP 36151G709.

The split was approved by stockholders on October 16, 2025; every 10 shares issued and outstanding will be combined into one share and outstanding equity awards and warrants will be proportionately adjusted. No fractional shares will be issued; holders entitled to fractions will receive a cash payment in lieu of a fractional share. Par value remains $0.01 and authorized shares remain at 100,000,000. Immediately after the reverse split, approximately 959,533 shares will be issued and outstanding.

Positive

• Reverse split reduces outstanding shares to ~959,533
• Trading continues on Nasdaq under INBS on Dec 16, 2025

Negative

• Fractional shares converted to cash payments for some holders
• Reverse split will not change percentage ownership except for cash‑in‑lieu cases

Key Figures

Reverse split ratio 1-for-10 Common stock reverse split approved and implemented December 2025

Effective time 11:59 pm ET, Dec 15 2025 Reverse split effectiveness time

Split-adjusted trading date Dec 16 2025 First trading day on Nasdaq post-split

New CUSIP 36151G709 CUSIP for INBS common stock after reverse split

Par value $0.01 per share Par value unchanged after reverse split

Authorized shares 100,000,000 shares Authorized common shares unchanged by split

Post-split shares outstanding Approximately 959,533 shares Common stock issued and outstanding immediately after split

Pre-split to post-split share exchange 10 old shares = 1 new share Automatic combination of issued and outstanding common stock

Market Reality Check

$0.7246 Last Close

Volume Volume 78,185 is below the 20-day average of 111,052 (relative volume 0.7x). normal

Technical Shares at 0.7246 are trading below the 200-day MA of 1.42 and about 73.65% under the 52-week high.

Peers on Argus

INBS was near its 52-week low before the reverse split. Peers like AIMD, NXL, ALUR, and NVNO show modest gains (up to 3.11%), while SINT is down 2.25%, indicating mixed sector trading and a stock-specific governance action for INBS.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 20	Conference participation	Neutral	-6.3%	Announcement of participation in Noble Capital Markets growth equity conference.
Nov 12	Earnings results	Positive	-1.7%	Record Q1 2026 revenue with higher margins and expanding customer base.
Nov 04	Preliminary revenue	Positive	-9.1%	Preliminary record Q1 revenue with strong sequential and YoY growth.
Oct 30	Customer growth	Positive	+8.3%	Added 33 new accounts and expanded total active accounts over 480.
Oct 23	Major UK contract	Positive	+3.0%	Secured major UK rollout for Intelligent Fingerprinting Drug Screening System.

Pattern Detected

Recent positive operational and financial updates often saw negative or muted next-day moves, with only some commercial wins translating into aligned price gains.

Recent Company History

Over the last few months, Intelligent Bio Solutions reported record fiscal Q1 2026 revenue, margin improvement, and strong customer growth, including 33 new accounts and a major UK contract with a multinational employer. Despite these positives, several updates, including preliminary revenue and final Q1 results, were followed by share price declines of up to 9.08%. The new reverse stock split follows earlier shareholder authorization tied to Nasdaq bid price compliance risk, extending a period of capital structure and listing-focused actions alongside commercial progress.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-25

An active S-3/A shelf was filed on 2025-08-25. The prospectus fragment describes Series J warrants with an initial exercise price of $1.90 per share, potentially exercisable into up to 4,046,456 shares upon stockholder approval. The shelf is noted as not effective in the provided data and has seen at least one related 424B5 usage.

Market Pulse Summary

The stock is dropping -20.4% following this news. A negative reaction despite the mechanical nature of a 1-for-10 reverse split would fit a pattern where prior fundamentally positive announcements sometimes saw selling, including declines of up to 9.08% after growth updates. The reverse split follows explicit Nasdaq minimum bid price compliance concerns and existing capital structure complexity, including an active S-3/A and Series J warrants, which could heighten perceptions of dilution risk and pressure sentiment around governance-driven actions.

Key Terms

reverse stock split financial

"today announced that it will effect a 1-for-10 reverse split of its common stock"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Nasdaq Capital Market regulatory

"Trading of the Company's common stock on The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

CUSIP financial

"under the trading symbol “INBS” and new CUSIP number 36151G709"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

warrants financial

"other equity rights, including warrants. No fractional shares will be issued"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

par value financial

"The par value of the common stock will remain unchanged at $0.01 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted basis, with the opening of the markets on December 16, 2025, under the trading symbol “INBS” and new CUSIP number 36151G709.

The reverse stock split was approved by Intelligent Bio Solutions’ stockholders at the annual meeting of the Company’s stockholders held on October 16, 2025, with the final ratio to be determined by the Company’s Board of Directors within the ratio range authorized by shareholders.

As a result of the reverse stock split, every 10 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.  In addition, proportionate adjustments will be made to outstanding equity-based awards and other equity rights, including warrants. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share. The par value of the common stock will remain unchanged at $0.01 per share after the reverse split, and the number of authorized shares of common stock will remain at 100 million shares. Immediately after the reverse stock split becomes effective, the Company will have approximately 959,533 shares of common stock issued and outstanding. The reverse split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent the reverse split results in a stockholder receiving a cash payment in lieu of a fractional share, as described above.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact: 
Intelligent Bio Solutions Inc. 
info@ibs.inc 
LinkedIn | Twitter

Investor & Media Contact: 
Valter Pinto, Managing Director    
KCSA Strategic Communications    
PH: (212) 896-1254    
INBS@kcsa.com     

FAQ

What reverse split ratio did Intelligent Bio Solutions (INBS) announce on December 12, 2025?

The company announced a 1‑for‑10 reverse stock split effective December 15, 2025 at 11:59 PM ET.

When will INBS trading reflect the reverse split on Nasdaq?

Trading will be split‑adjusted at the market open on December 16, 2025 under the symbol INBS.

How many INBS shares will be outstanding immediately after the December 15, 2025 reverse split?

Immediately after the reverse split the company will have approximately 959,533 shares issued and outstanding.

Will Intelligent Bio Solutions issue fractional INBS shares after the reverse split?

No; holders entitled to fractional shares will receive a cash payment in lieu of fractional shares.

Did Intelligent Bio Solutions receive shareholder approval for the INBS reverse split?

Yes; stockholders approved the reverse split at the annual meeting on October 16, 2025.

Will INBS equity awards and warrants change after the reverse split?

Yes; outstanding equity‑based awards and warrants will be proportionately adjusted to reflect the 1‑for‑10 split.